RBC Capital analyst Brian Abrahams raised the firm’s price target on Regeneron (REGN) to $765 from $745 and keeps a Sector Perform rating on the shares. The firm is positive on the company’s R&D engine and sees the underappreciated medium-term growth from dupi, pipeline, and the Sanofi (SNY) repayment, the analyst tells investors in a research note. RBC adds however that shares may continue to trade at a discount, pressured by Eylea headwinds and dupi LOE uncertainty
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on REGN:
- Regeneron, Sanofi announces EMA for CHMP adopted positive opinion for Dupixent
- Regeneron, Sanofi announce FDA approval of Dupixent for AFRS
- Here is a List of Small-Cap Biotech ETFs to Watch for Big Gains in 2026
- Regeneron announces FDA accepted Priority Review for BLA for garetosmab
- The Week That Was, The Week Ahead: Macro and Markets, Feb. 15